Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus

Article Abstract:

Nevirapine appears to be well tolerated and have some beneficial effect in HIV-infected patients. Nevirapine is an antiviral drug that inhibits enzymes involved in the reproduction of HIV. Researchers conducted a clinical trial of nevirapine alone and in combination with zidovudine, another antiviral drug, among 62 HIV-infected patients. Patients received doses of 12.5, 50 and 200 milligrams (mg) of nevirapine alone or in combination with 200 mg doses of zidovudine every eight hours. By day 7 of the trial, blood levels of HIV infection markers fell to a minimum level in the majority of patients. Blood levels of HIV genetic material decreased by at least 50% after four weeks of treatment in four of ten patients receiving either 50 mg or 200 mg of nevirapine. Most patients experienced fatigue or extreme sleepiness as a side effect of the drug. Other side effects included headache, diarrhea, nausea, fever and rash.

Testing

---

Simultaneous vs Sequential Initiation of Therapy With Indinavir, Zidovudine, and Lamivudine for HIV-1 Infection

Article Abstract:

Simultaneous treatment with three antiviral medications appears to be substantially more effective at reducing viral loads than sequential use of the drugs in HIV infection. Researchers treated 97 HIV patients with indinavir, zidovudine, and lamivudine together or sequentially. Seventy-eight percent of patients who received the simultaneous three-drug regimen achieved clinically significant viral load reductions, which persisted at 100 weeks. Only 30-45% of those who took the drugs in sequence achieved the same level of viral suppression.

Indinavir, Dosage and administration, Drug therapy, Combination, Combination drug therapy, Lamivudine

---

Phase 1 study of combination therapy with L-697,661 and zidovudine

Article Abstract:

The combined use of two or more drugs against HIV may reduce the chances that the virus will become resistant to either drug. This was the result of the ACTG 184 study, which evaluated a new anti-HIV drug called L-697,661. Six HIV-infected patients took L-697,661 and zidovudine and seven took L-697,661 alone. The virus became rapidly resistant to L-697,661 in those who took L-697,661 alone, but this did not occur in those who took both drugs. L-697,661 belongs to the class of drugs called non-nucleoside reverse transcriptase inhibitors.

Similar abstracts:

• Abstracts: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study
• Abstracts: Targeting a foreign protein into virion particles by fusion with the Vpx protein of simian immunodeficiency virus
• Abstracts: The effect of lipid peroxides on isolated human umbilical artery contraction. Human umbilical vessels: responses to agents frequently used in obstetric patients
• Abstracts: Temporal associations of human papillomavirus infection with cervical cytological abnormalities. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance
• Abstracts: Public health programs faring OK so far, but cuts still possible. Does America really need a Surgeon General?

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.